- Purpose of This Guideline
- Risk of Infection Following an Exposure to HIV
- Rationale for PEP and Evidence of PEP Effectiveness
- First Dose of PEP and Management of the Exposure Site
- Exposure Risk Evaluation
- Source HIV Status and Management
- Baseline Testing of the Exposed Individual
- Selecting and Initiating a 28-Day Course of PEP
- Counseling and Patient Education
- Providing PEP Medications and Other Services
- Follow-Up of the Exposed Individual
- Sequential HIV Testing and Laboratory Monitoring
- Management of Potential Exposure to Hepatitis B Virus
- Management of Potential Exposure to Hepatitis C Virus
- All Recommendations
- All Good Practices
- All Tables, Figures, and Boxes
- Supplementary Materials
- Purpose of This Guideline
- PrEP for Individuals at Risk of Acquiring HIV
- Choosing and Prescribing a PrEP Regimen
- Laboratory Testing Before PrEP Initiation
- Ongoing Laboratory Testing
- Managing a Positive HIV Test Result
- Discontinuing PrEP
- Appendix: Care Provider Checklists for PrEP Initiation, Regimen Choice, and Follow-Up
- All Recommendations
- PrEP Payment Options
- Guidance for HIV Testing of Sexual Assault Defendants
- Clinical Guidelines Program Approach to Shared Decision-Making
- NYSDOH HIV Care Provider Definitions
- Use of Dolutegravir in Individuals of Childbearing Capacity
- GOALS Framework for Sexual History Taking in Primary Care
- NYSDOH Health Equity Competencies for Health Care Providers
- Selected Links: Resources for Clinicians
- Selected Links: Resources for Consumers
- All FDA-Approved HIV Medications, With Brand Names and Abbreviations